| Reni, Michele |
| Recruiting | 4 | 175 | Europe | PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy | IRCCS San Raffaele | Pancreatic Ductal Adenocarcinoma | 01/22 | 01/26 | | |
ASPIRE, NCT05254171: Study of Nab-Paclitaxel and Gemcitabine With or Without SBP-101 in Pancreatic Cancer |
|
|
| Recruiting | 2/3 | 600 | Europe, US, RoW | SBP-101, ivospemin, Nab-paclitaxel, Abraxane, Gemcitabine, Gemzar, Placebo | Panbela Therapeutics, Inc. | Pancreatic Cancer Metastatic, Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer Stage IV | 08/26 | 01/27 | | |
CASSANDRA, NCT04793932: Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG ( TRIAL) |
|
|
| Recruiting | 2 | 261 | Europe | PAXG, mFOLFIRINOX, short-course chemotherapy, long-course chemotherapy | Associazione Italiana per lo Studio del Pancreas, High Research srl, Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente | Pancreas Ductal Adenocarcinoma | 11/21 | 11/23 | | |
| Active, not recruiting | 2 | 250 | Europe, Canada, Japan, US, RoW | zenocutuzumab (MCLA-128), bispecific, MCLA-128 | Merus N.V. | Solid Tumours Harboring NRG1 Fusion, NSCLC Harboring NRG1 Fusion, Pancreatic Cancer Harboring NRG1 Fusion, NRG1 Fusion | 12/26 | 12/26 | | |
SALE, NCT04692740: Chlorambucil in Metastatic PDAC Patients Bearing a Germ Line DNA Defects Repair Mutations ( Trial) |
|
|
| Active, not recruiting | 2 | 20 | Europe | Chlorambucil, Oral, 2 Mg | Michele Reni | Pancreatic Ductal Adenocarcinoma | 01/23 | 12/23 | | |
| Recruiting | 2 | 18 | Europe | Decitabine 50 MG [Dacogen], Dacogen | Luca Cardone, Anticancer Fund, Belgium, Azienda Ospedaliera Universitaria Integrata Verona, Catholic University of the Sacred Heart, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, San Raffaele University Hospital, Italy, University of Pisa | Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma Recurrent | 02/24 | 02/25 | | |
| Recruiting | 2 | 240 | Europe | Valproic acid, Simvastatin 20mg, Gemcitabine 1000 mg, Nab paclitaxel, Cisplatin, Capecitabine | National Cancer Institute, Naples, Ministero della Salute (progetto RF-2021-12371995), Remedi4All EU project (Project number: 101057442; HORIZON-HLTH-2021-DISEASE-04-02) | Adenocarcinoma of the Pancreas | 08/25 | 06/26 | | |
LUMACA, NCT04435067: Evaluation of Clinical, Radiomics and Molecular Features of Lung Metastasis in PDAC Patients ( Trial) |
|
|
| Recruiting | N/A | 44 | Europe | Analysis of genetic mutations and the gene expression profile of lung metastasis and primary neoplasia, Radiomics analysis on TAC imaging at diagnosis of lung metastasis and, if possible, of the primary tumor | IRCCS San Raffaele | Pancreas Adenocarcinoma | 12/21 | 12/21 | | |
| Recruiting | N/A | 475 | Europe | | IRCCS San Raffaele, Università Vita-Salute San Raffaele | Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Cancer (CRC), Liver Metastasis | 06/26 | 06/26 | | |
| Avallone, Antonio |
| Active, not recruiting | 3 | 530 | Europe, RoW | Toripalimab combined with Lenvatinib, Placebo combined with Lenvatinib | Shanghai Junshi Bioscience Co., Ltd., Shanghai Junshi Biosciences Co., Ltd | Advanced Hepatocellular Carcinoma (HCC) | 05/25 | 09/26 | | |
IMPROVE-2, NCT06509126: Intermittent or Continuous Panitumumab Plus FOLFIRI for Left Sided RAS/B-RAF Wild-type Metastatic Colorectal Cancer |
|
|
| Recruiting | 3 | 500 | Europe | Panitumumab, Vectibix, Irinotecan, Campto, 5-fluorouracil, 5-FU, L-folinic acid, LFA | National Cancer Institute, Naples | Colorectal Cancer Stage IV | 01/28 | 06/28 | | |
| Active, not recruiting | 3 | 450 | Europe, Japan, US, RoW | Regorafenib, Stivarga, Nivolumab, Opdivo, Docetaxel, Taxotere, Paclitaxel, Abraxane, Irinotecan, Camptosar, Trifluridine/Tipracil, Lonsurf | Australasian Gastro-Intestinal Trials Group, Bayer, Bristol-Myers Squibb, University of Sydney, Academic and Community Cancer Research United, Taiwanese Cooperative Oncology Group, Frankfurter Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest, National Cancer Center Hospital East, Syneos Health | Gastro-Oesophageal Cancer | 06/25 | 06/26 | | |
FIRST-308, NCT05948475: Study of Tinengotinib VS. Physician's Choice a Treatment of Subjects With FGFR-altered in Cholangiocarcinoma |
|
|
| Recruiting | 3 | 200 | Europe, US, RoW | Tinengotinib 8 mg, Tinengotinib 10 mg, Physician's Choice | TransThera Sciences (Nanjing), Inc. | Cholangiocarcinoma | 05/26 | 08/26 | | |
REVOLUTION, NCT04310176: Valproic Acid in Combination With Bevacizumab and Oxaliplatin/Fluoropyrimidine Regimens in Patients With Ras-mutated Metastatic Colorectal Cancer |
|
|
| Recruiting | 2 | 200 | Europe | Bevacizumab, mFOLFOX6 regimen, mOXXEL regimen, Valproic acid, Capecitabine, 5-fluorouracil | National Cancer Institute, Naples | Ras-mutated Metastatic Colorectal Cancer | 12/23 | 11/24 | | |
| Recruiting | 2 | 18 | Europe | Decitabine 50 MG [Dacogen], Dacogen | Luca Cardone, Anticancer Fund, Belgium, Azienda Ospedaliera Universitaria Integrata Verona, Catholic University of the Sacred Heart, Istituto Nazionale Tumori IRCCS - Fondazione G. Pascale, San Raffaele University Hospital, Italy, University of Pisa | Pancreatic Adenocarcinoma Metastatic, Pancreatic Adenocarcinoma Recurrent | 02/24 | 02/25 | | |
| Active, not recruiting | 2 | 46 | Europe | regorafenib | National Cancer Institute, Naples | Advanced Colorectal Cancer | 11/24 | 11/24 | | |
VICTORIA, NCT06714357: ValproIc Acid to Potentiate Anti-EGFR Treatment Efficacy and Prevent/revert Resistance in Colorectal Cancer |
|
|
| Not yet recruiting | 2 | 130 | Europe | irinotecan, panitumumab, Valproic Acid (VPA) | National Cancer Institute, Naples | Colorectal Cancer Metastatic | 12/26 | 06/27 | | |
CAVE 2, NCT05291156: CAVE-2 GOIM Study: a Clinical Study of the Combination of Avelumab Plus Cetuximab as Rechallenge Strategy |
|
|
| Recruiting | 2 | 173 | Europe | Cetuximab, Erbitux, Avelumab, Bavencio | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Cancer | 07/25 | 07/25 | | |
| Recruiting | 2 | 240 | Europe | Valproic acid, Simvastatin 20mg, Gemcitabine 1000 mg, Nab paclitaxel, Cisplatin, Capecitabine | National Cancer Institute, Naples, Ministero della Salute (progetto RF-2021-12371995), Remedi4All EU project (Project number: 101057442; HORIZON-HLTH-2021-DISEASE-04-02) | Adenocarcinoma of the Pancreas | 08/25 | 06/26 | | |
| Active, not recruiting | 2 | 219 | Europe | Cetuximab, Erbitux, FOLFIRI, FOLFOX regimen, FOLFOX, Irinotecan | University of Campania "Luigi Vanvitelli" | Metastatic Colorectal Adenocarcinoma | 08/25 | 06/26 | | |
NCT01898104: Preoperative Valproic Acid and Radiation Therapy for Rectal Cancer |
|
|
| Recruiting | 1/2 | 152 | Europe | preoperative radiation therapy, Valproic Acid, Capecitabine | National Cancer Institute, Naples | Colorectal Cancer | 11/23 | 04/24 | | |
| Recruiting | N/A | 400 | Europe, RoW | MRD | Exact Sciences Corporation, Labcorp Corporation of America Holdings, Inc | Colorectal Cancer | 06/29 | 06/29 | | |
PETRA2 - CRC, NCT02618850: PET/CT Scan as a Tool to Rationalize the Treatment of Patients With Advanced ColoRectal Cancer Undergoing First-line Medical Treatment |
|
|
| Active, not recruiting | N/A | 260 | Europe | PET/CT, first-line chemotherapy | National Cancer Institute, Naples | Colorectal Cancer Stage IV | 12/24 | 12/24 | | |
